The phase 3 LEAP-011 study evaluated pembrolizumab plus lenvatinib vs placebo in 441 adults with histologically confirmed, locally advanced or metastatic urothelial carcinoma.
The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.
The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.
The network meta-analysis aimed to compare various combinations of treatment options to determine the safest and most effective management strategy for mCSPC.
The investigational product targets CD70, which is highly expressed in renal cell carcinoma with limited normal tissue expression.
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
The study included a total of 183 patients with genitourinary cancers.
Investigators conducted a noninterventional, multicenter study (APOLON) in patients receiving frontline pazopanib therapy.
Patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy were included in the analysis.
Study authors analyzed a total of 46 Black men with advanced prostate cancer enrolled in the phase 3 HERO study.
